Management Team

Elizabeth L. R. Donley, JD, MBA, MS
Chief Executive Officer, Member of the Board of Directors
Elizabeth L. R. Donley, JD, MBA, MS

Ms. Donley brings a unique combination of business and legal experience to Stemina. She has more than twenty years of experience in intellectual property, law and business management. Ms. Donley served as General Counsel and Director of Business Development for the Wisconsin Alumni Research Foundation (WARF) for more than eight years. During those eight years, Ms. Donley negotiated hundreds of licenses, sponsored research and collaboration agreements between industry and WARF, the intellectual property management organization for the University of Wisconsin. Ms. Donley also served as Managing Director of both WARF subsidiaries: WiSys Technology Foundation (WiSys) and WiCell Research Institute (WiCell). WiCell distributes human embryonic stem (hES) cells, trains researchers worldwide and conducts important research involving many aspects of hES cell research. In 2005, WiCell was awarded a $16 million contract by the National Institute of Health to serve as the National Stem Cell Bank.

Prior to joining WARF in 1998, Ms. Donley practiced law with the law firm of Quarles & Brady in the areas of intellectual property law, business transactions, securities and corporate law.

Robert E. Burrier, Ph.D.
Chief Operating Officer, Vice President of Research and Development
Robert E. Burrier, Ph.D.

Dr. Burrier is a career technology executive with experience in pharmaceutical research, ‘biosupplier’ product development, and biotech services. While working in pharma, he participated and led programs resulting in drugs currently on the market including Zetia, Vytorin, and others. He is very experienced in assays and paradigms used for drug discovery having participated in over 150 drug discovery programs while working for Schering-Plough, Eli Lilly, GelTex, and Genzyme. In the Biosupplier arena, Dr. Burrier led teams to innovate on an ongoing basis in the areas of cell biology, cell media development, assay development, and workflow improvements with companies including Invitrogen, and EMD Millipore (Merck). The markets around which these programs were based include academic and industrial cell biology research, stem cells and regenerative medicine, as well as biotherapeutic protein production. Dr. Burrier joined Stemina to bring his expertise of cell biology, assay development, scientific operations, program management, and organizational effectiveness to facilitate success and to continue to fulfill his interest of continually improving human health.

Paul R. West, Ph.D.
Director of BioAnalytical Technology
Paul R. West, Ph.D.

Dr. West is an expert in small molecule mass spectrometry including LC/MS, MS/MS, HRMS, and solving unknown structures using those methods. He has thorough knowledge of cGLP/cGMP including qualitative analytical method development and validation. He has over 15 years of experience using a variety of analytical techniques focusing on structural determination for both known and unknown compounds.

Prior to working for Stemina, Dr. West worked for Abbott Laboratories as an associate research investigator in the Structural Chemistry Department where he implemented and coordinated analytical projects for the Global Pharmaceutical Research Division.

Fred R. Kirchner, Ph.D.
Director of Toxicology
Fred R. Kirchner, Ph.D.

Dr. Kirchner has over 33 years of work in the field of Toxicology in the pharmaceutical industry, consumer product development, and environmental assessment for the Department of Energy. He obtained his PhD in Radiation Biology from the University of Iowa in 1979, and received postdoctoral training at Argonne National Laboratory assessing the toxicology of fossil fuel by-products. In 1984 he joined the Colgate Palmolive Co, conducting GLP consumer product safety testing. In 1988 he joined Ciba-Geigy, as a study director and eventually manager of Toxicologists, conduction GLP safety assessments of new drug candidates. In 1992 he served as Associate Director of Toxicology with SmithKline-Beecham, overseeing the Study Directors and the technical group. Dr. Kirchner conducted environmental toxicology assessments for DOE’s Argonne National Lab in 1995. He then joined American Home Products (Wyeth) in 1998, where he served as Director of Toxicology until 2007. His most recent position was as Executive Director of Toxicology at Covance Laboratories, where he supervised the Toxicology, Pathology, and Safety Pharmacology departments. He has also served as a member of the Board of Directors of the American Board of Toxicology from 2006 to 2010. Dr. Kirchner joined Stemina to bring his expertise of drug development and management of programs to continue to help bring the miracles of modern medicine to the public.

Joseph J. King, Ph.D.
Director of Computational Biology
Joseph J. King, Ph.D.

Dr. King is a proven leader and mentor in the field of scientific programming and bioinformatics with over 30 years of experience.  During his fourteen-year tenure leading the development of the  genetics computer group (GCG) package, Dr. King developed the processes and led the bioinformatics teams needed to support a large commercial software suite.  The GCG package quickly became the staple for bioinformatics analysis everywhere.

In 2005, Dr. King joined Third Wave Technologies as a bioinformatics scientist which allowed him to contribute to the development of the company’s molecular diagnostic tests.  During his tenure at Third Wave/Hologic, Dr. King created innovative solutions to help the company secure FDA approval for its diagnostic test, well ahead of much larger competitors.  At Third Wave/Hologic, Dr. King demonstrated the ability to adapt to the needs of the business working in the roles of Principal Scientist, Senior Manager and Director of Bioinformatics.  In his various roles, Dr. King learned an appreciation for the complexity, skill, and dedication necessary to bring diagnostic products to market. Dr. King brings experience in innovation and management of bioinformatics teams to Stemina as the Company begins its clinical study for its autism diagnostic.

Dr. King received his PhD in Genetics from the University of Georgia and his MS in Genetics from the Iowa State University.

Alan M. Smith, Ph.D.
Associate Director of Computational Biology
Alan M. Smith, Ph.D.

Dr. Alan Smith is the Associate Director of Computational Biology. His expertise is in the areas of experimental design, data analysis, and bioinformatics to identify metabolic signatures and generate predictive models. Dr. Smith was a postdoctoral fellow at the University of Wisconsin-Madison in Dr. Gabriela Cezar’s laboratory where he developed laboratory methods for metabolomics of cell culture and tissue based experiments, as well as a metabolomics data analysis pipeline that are the foundation of Stemina’s metabolomics platform. Dr. Smith completed his Bachelor’s and Master’s Degrees in Biology at Purdue University and received his Ph.D. from the University of Wisconsin-Madison in Plant Breeding and Plant Genetics. His expertise is in epigenetics, metabolomics, and computational biology.